Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune Disease

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Reily, Colin ^a   Ueda, Hiroyuki ^a   Huang, Zhi Qiang ^a   Mestecky, Jiri ^a,b   Julian, Bruce A ^a,b   Willey, Christopher D ^c   Novak, Jan ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOSE; GLYCOSYLTRANSFERASE; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN A;

ANTIGEN ANTIBODY COMPLEX; GLYCOSYLATION; HINGE REGION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN PRODUCTION; INTRACELLULAR SIGNALING; NONHUMAN; REVIEW; ANIMAL; AUTOIMMUNE DISEASE; BLOOD; GENE LOCUS; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNE DISEASES; GALACTOSE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GLOMERULONEPHRITIS, IGA; GLYCOSYLATION; GLYCOSYLTRANSFERASES; HUMANS; IMMUNOGLOBULIN A; SIGNAL TRANSDUCTION;

EID: 84919716549     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/197548     Document Type: Review

References (77)

1. J. Berger and N. Hinglais, "Intercapillary deposits of IgA-IgG, " Journal d'Urologie et de Néphrologie, vol. 74, pp. 694-695, 1968.
2. R. J. Wyatt and B. A. Julian, "IgA nephropathy, " New England Journal of Medicine, vol. 368, pp. 2402-2414, 2013.
3. S. J. Barbour and H. N. Reich, "Risk stratification of patients with IgA nephropathy, " American Journal of Kidney Diseases, vol. 59, pp. 865-873, 2012.
4. G. D'Amico, "Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors, " American Journal of Kidney Diseases, vol. 36, no. 2, pp. 227-237, 2000.
5. G. Canaud, V. Audard, T. Kofman, P. Lang, C. Legendre, and P. Grimbert, "Recurrence from primary and secondary glomerulopathy after renal transplant, " Transplant International, vol. 25, no. 8, pp. 812-824, 2012.
6. A. M. Herzenberg, A. B. Fogo, H.N. Reich et al., "Validation of the Oxford classification of IgA nephropathy, " Kidney International, vol. 80, pp. 310-317, 2011.
7. R. Coppo, S. Troyanov, R. Camilla et al., "The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults, " Kidney International, vol. 77, pp. 921-927, 2010.
8. D. C. Cattran, R. Coppo, H. T. Cook et al., "The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification, " Kidney International, vol. 76, pp. 534-545, 2009.
9. M. E. Conley, M. D. Cooper, and A. F. Michael, "Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus, " Journal of Clinical Investigation, vol. 66, pp. 1432-1436, 1980.
10. J.Mestecky, I.Moro, andM. Kerr, "Mucosal immunoglobulins, " in Mucosal Immunology, J. Mestecky, M. Lamm, J. McGhee, J. Bienenstock, L. Mayer, and W. Strober, Eds., pp. 153-181, Elsevier, 2009.
11. T. S. Mattu, R. J. Pleass, A. C. Willis et al., "The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions, " Journal of Biological Chemistry, vol. 273, pp. 2260-2272, 1998.
12. M.C. Field, R. A. Dwek, C. J. Edge, and T.W. Rademacher, "Olinked oligosaccharides from human serum immunoglobulin A1, " Biochemical Society Transactions, vol. 17, pp. 1034-1035, 1989.
13. M. Tomana, W. Niedermeier, J. Mestecky, and F. Skvaril, "The differences in carbohydrate composition between the subclasses of IgA immunoglobulins, " Immunochemistry, vol. 13, pp. 325-328, 1976.
14. J.Mestecky, M. Tomana, P.A.Crowley-Nowick, Z.Moldoveanu, B. A. Julian, and S. Jackson, "Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy, " Contributions to Nephrology, vol. 104, pp. 172-182, 1993.
15. J. M. Woof and J. Mestecky, "Mucosal immunoglobulins, " in Mucosal Immunology, J. Mestecky, W. Strober, M. W. Russell, B. Kelsall, H. Cheroutre, and B. Lambrecht, Eds., 4th edition, 2014, In press.
16. M. E. Koshland, "The coming of age of the immunoglobulin J chain, " Annual Review of Immunology, vol. 3, pp. 425-453, 1985.
17. H. Suzuki, M. Raska, K. Yamada et al., "Cytokine-mediated dysregulation of specific glycosyltransferases contributes to aberrant glycosylation of IgA1 in patients with IgA nephropathy, " Journal of the American Society of Nephrology, vol. 23, p. 854A, 2012.
18. P. M. Andre, P. Le Pogamp, and D. Chevet, "Impairment of jacalin binding to serum IgA in IgA nephropathy, " Journal of Clinical Laboratory Analysis, vol. 4, pp. 115-119, 1990.
19. A. C. Allen, E.M. Bailey, J. Barratt, K. S. Buck, and J. Feehally, "Analysis of IgA1O-glycans in IgAnephropathy by fluorophoreassisted carbohydrate electrophoresis, " Journal of the American Society of Nephrology, vol. 10, pp. 1763-1771, 1999.
20. M. Tomana, K. Matousovic, B. A. Julian, J. Radl, K. Konecny, and J. Mestecky, "Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG, " Kidney International, vol. 52, pp. 509-516, 1997.
21. Y. Hiki, H. Odani, M. Takahashi et al., "Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy, " Kidney International, vol. 59, pp. 1077-1085, 2001.
22. A. C. Allen, E.M. Bailey, P. E. Brenchley, K. S. Buck, J. Barratt, and J. Feehally, "Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients, " Kidney International, vol. 60, pp. 969-973, 2001.
23. J. Feehally andA. C.Allen, "Structural features of IgAmolecules which contribute to IgA nephropathy, " Journal of Nephrology, vol. 12, pp. 59-65, 1999.
24. A. G. Gharavi, Z. Moldoveanu, R. J. Wyatt et al., "Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy, " Journal of theAmericanSociety ofNephrology, vol. 19, pp. 1008-1014, 2008.
25. J. Novak, W. J. Cook, B. A. Julian, J. Mestecky, and M. Tomana, "IgA nephropathy (IgAN): a similarity in the mechanism of IgA1 deposition in the kidney in humans and mice, " Journal of the American Society of Nephrology, vol. 11, pp. 478-479A, 2000.
26. M. Tomana, R. Kulhavy, and J. Mestecky, "Receptor-mediated binding and uptake of immunoglobulin A by human liver, " Gastroenterology, vol. 94, pp. 762-770, 1988.
27. M. Tomana, J. O. Phillips, R. Kulhavy, and J. Mestecky, "Carbohydrate-mediated clearance of secretory IgA from the circulation, " Molecular Immunology, vol. 22, pp. 887-892, 1985.
28. J. Novak, B. A. Julian, M. Tomana, and J.Mestecky, "Progress in molecular and genetic studies of IgA nephropathy, " Journal of Clinical Immunology, vol. 21, no. 5, pp. 310-327, 2001.
29. P. J. van der Boog, C. van Kooten, J. W. de Fijter, and M. R. Daha, "Role of macromolecular IgA in IgA nephropathy, " Kidney International, vol. 67, pp. 813-821, 2005.
30. J. K. Boyd and J. Barratt, "Immune complex formation in IgA nephropathy: CD89 a "saint" or a "sinner"?" Kidney International, vol. 78, pp. 1211-1213, 2010.
31. T. Kokubo, Y. Hiki, H. Iwase et al., "Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins, " Journal of theAmerican Society of Nephrology, vol. 9, pp. 2048-2054, 1998.
32. H. Suzuki, R. Fan, Z. Zhang et al., "Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity, " Journal of Clinical Investigation, vol. 119, pp. 1668-1677, 2009.
33. M. Tomana, J. Novak, B. A. Julian, K. Matousovic, K. Konecny, and J. Mestecky, "Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies, " Journal of Clinical Investigation, vol. 104, pp. 73-81, 1999.
34. J. Novak, Z. Moldoveanu, M. B. Renfrow et al., "IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells, " Contributions to Nephrology, vol. 157, pp. 134-138, 2007.
35. J. Feehally, M. Farrall, A. Boland et al., "HLA has strongest association with IgA nephropathy in genome-wide analysis, " Journal of the American Society of Nephrology, vol. 21, pp. 1791-1797, 2010.
36. A. G. Gharavi, K. Kiryluk, M. Choi et al., "Genome-wide association study identifies susceptibility loci for IgA nephropathy, " Nature Genetics, vol. 43, pp. 321-327, 2011.
37. X. Q. Yu, M. Li, H. Zhang et al., "A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy, " Nature Genetics, vol. 44, no. 2, pp. 178-182, 2012.
38. M. Fennessy, G. A. Hitman, R.H.Moore et al., "HLA-DQgene polymorphism in primary IgA nephropathy in three European populations, " Kidney International, vol. 49, pp. 477-480, 1996.
39. K. Kiryluk, Y. Li, S. Sanna-Cherchi et al., "Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis, " PLOS Genetics, vol. 8, Article ID e1002765, 2012.
40. K. Kiryluk, J. Novak, and A. G. Gharavi, "Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies, " Annual Review of Medicine, vol. 64, pp. 339-356, 2013.
41. P. C. Heinrich, I. Behrmann, S. Haan, H. M. Hermanns, G. Muller-Newen, and F. Schaper, "Principles of interleukin (IL)-6-type cytokine signalling and its regulation, " Biochemical Journal, vol. 374, pp. 1-20, 2003.
42. G. Rostoker, J. C. Rymer, G. Bagnard, M. Petit-Phar, M. Griuncelli, and Y. Pilatte, "Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis, and a potential target of immunoglobulin therapy?" Clinical & Experimental Immunology, vol. 114, pp. 468-476, 1998.
43. J. V. Stein, M. Lopez-Fraga, F. A. Elustondo et al., "APRIL modulates B and T cell immunity, " Journal of Clinical Investigation, vol. 109, pp. 1587-1598, 2002.
44. K. Harada, Y. Akai, N. Kurumatani, M. Iwano, and Y. Saito, "Prognostic value of urinary interleukin 6 in patients with IgA nephropathy: an 8-year follow-up study, " Nephron, vol. 92, no. 4, pp. 824-826, 2002.
45. J. Novak, M. Raska, M. Tomana et al., "Transcriptional regulation by cytokines of O-glycan-specific glycosyltransferases in human IgA1-producing cells: implications for IgA nephropathy (IgAN), " Journal of the American Society of Nephrology A, vol. 14, p. 632A, 2003.
46. H. Suzuki, M. Raska, K. Yamada et al., "Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes, " Journal of Biological Chemistry, vol. 289, pp. 5330-5339, 2014.
47. T. Knoop, B. E. Vikse, E. Svarstad, S. Leh, A. V. Reisater, and R. Bjorneklett, "Mortality in patients with IgA nephropathy, " American Journal of Kidney Diseases, vol. 62, no. 5, pp. 883-890, 2013.
48. J. Lv, D. Xu, V. Perkovic et al., "Corticosteroid therapy in IgA nephropathy, " Journal of theAmericanSociety ofNephrology, vol. 23, pp. 1108-1116, 2012.
49. Y. Hiki, "O-linked oligosaccharides of the IgA1 hinge region: roles of its aberrant structure in the occurrence and/or progression of IgA nephropathy, " Clinical and Experimental Nephrology, vol. 13, pp. 415-423, 2009.
50. F. Berthoux, H. Suzuki, L. Thibaudin et al., "Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy, " Journal of the American Society of Nephrology, vol. 23, pp. 1579-1587, 2012.
51. N. Zhao, P. Hou, J. Lv et al., "The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression, " Kidney International, vol. 82, no. 7, pp. 790-796, 2012.
52. H. Suzuki, Z. Moldoveanu, S. Hall et al., "IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1, " Journal of Clinical Investigation, vol. 118, pp. 629-639, 2008.
53. E. Losev, C. A. Reinke, J. Jellen, D. E. Strongin, B. J. Bevis, and B. S. Glick, "Golgi maturation visualized in living yeast, " Nature, vol. 441, pp. 1002-1006, 2006.
54. H. Schachter, "Coordination between enzyme specificity and intracellular compartmentation in the control of protein-bound oligosaccharide biosynthesis, " Biology of the Cell, vol. 51, pp. 133-145, 1984.
55. B. C. O'Connell and L. A. Tabak, "A comparison of serine and threonine O-glycosylation by UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, " Journal of Dental Research, vol. 72, pp. 1554-1558, 1993.
56. M. Raska, K. Yamada, M. Horynova et al., "Role of GalNActransferases in the synthesis of aberrant IgA1 O-glycans in IgA nephropathy, " Journal of theAmericanSociety ofNephrology, vol. 22, p. 625A, 2011.
57. D. H. van den Eijunden, P. Stoffyn, A. Stoffyn, and W. E. Schiphorst, "Specificity of sialytransferase: structure of α1-acid glycoprotein sialylated in vitro. A new methodology for the determination of the structure of the linkage formed by glycosyltransferase action on galactosyl-oligosaccharide-protein acceptors, " European Journal of Biochemistry, vol. 81, pp. 1-7, 1977.
58. T. Kudo, T. Iwai, T. Kubota et al., "Molecular cloning and characterization of a novel UDP-Gal:GalNAc(α) peptide β 1, 3-galactosyltransferase (C1Gal-T2, an enzyme synthesizing a core 1 structureofO-glycan, " Journal of Biological Chemistry, vol. 277, pp. 47724-47731, 2002.
59. R. P. Aryal, T. Ju, and R. D. Cummings, "Tight complex formation between Cosmc chaperone and its specific client non-native T-synthase leads to enzyme activity and clientdriven dissociation, " Journal of Biological Chemistry, vol. 287, pp. 15317-15329, 2012.
60. J. E. Sadler, J. I. Rearick, and R. L. Hill, "Purification to homogeneity and enzymatic characterization of an α-Nacetylgalactosaminide α2→6 sialyltransferase from porcine submaxillary glands, " Journal of Biological Chemistry, vol. 254, pp. 5934-5941, 1979.
61. T. Ju, V. I. Otto, and R. D. Cummings, "The Tn antigenstructural simplicity and biological complexity, " Angewandte Chemie International Edition in English, vol. 50, no. 8, pp. 1770-1791, 2011.
62. J. Novak, Z. Moldoveanu, B. A. Julian et al., "Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system, " Advances in Otolaryngology, vol. 72, pp. 60-63, 2011.
63. K. Yamaguchi, Y. Ozono, T. Harada, and K. Hara, "Changes in circulating immune complex and charge distribution with upper respiratory tract inflammation in IgA nephropathy, " Nephron, vol. 69, no. 4, pp. 384-390, 1995.
64. J. Novak, M. B. Renfrow, A. G. Gharavi, and B. A. Julian, "Pathogenesis of immunoglobulin A nephropathy, " Current Opinion in Nephrology and Hypertension, vol. 22, pp. 287-294, 2013.
65. R. Coppo, A. Amore, B. Gianoglio et al., "Macromolecular IgA and abnormal IgA reactivity in sera from children with IgA nephropathy. Italian Collaborative Paediatric IgA Nephropathy Study, " Clinical Nephrology, vol. 43, no. 1, pp. 1-13, 1995.
66. J. Novak, B. A. Julian, M. Tomana, and J. Mestecky, "IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy, " Seminars in Nephrology, vol. 28, pp. 78-87, 2008.
67. D. D. McCarthy, J. Kujawa, C. Wilson et al., "Mice overexpressing BAFF develop a commensal flora-dependent, IgAassociated nephropathy, " Journal of Clinical Investigation, vol. 121, pp. 3991-4002, 2011.
68. J. S. Silver and C. A. Hunter, "gp130 at the nexus of inflammation, autoimmunity, and cancer, " Journal of Leukocyte Biology, vol. 88, no. 6, pp. 1145-1156, 2010.
69. A. Davidson, "The rationale for BAFF inhibition in systemic lupus erythematosus, " Current Rheumatology Reports, vol. 14, pp. 295-302, 2012.
70. A. Cerutti, I. Puga, and M. Cols, "Innate control of B cell responses, " Trends in Immunology, vol. 32, no. 5, pp. 202-211, 2011.
71. G. Xin, W. Shi, L. X. Xu, Y. Su, L. J. Yan, and K. S. Li, "Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features, " Journal of Nephrology, vol. 26, pp. 683-690, 2013.
72. C. Reily, K. Yamada, Z. Q. Huang et al., "Abnormal STAT3 signaling enhances production of autoantigen in an autoimmune disease, IgA nephropathy, " Journal of the American Society of Nephrology, vol. 24, p. 20A, 2013.
73. H. Suzuki, Z. Moldoveanu, S. Hall et al., "Cytokines regulate aberrant glycosylation of IgA1 in cell lines from patients with IgA nephropathy, " Journal of the American Society of Nephrology, vol. 18, p. 188A, 2007.
74. K. Yamada, Z. Q. Huang, M. Raska et al., "Effects of leukemia inhibitory factor and oncostatin M on IgA1-producing cells from patients with IgA nephropathy, " Journal of the American Society of Nephrology, vol. 23, p. 912A, 2012.
75. J. Chia, G. Goh, V. Racine, S. Ng, P. Kumar, and F. Bard, "RNAi screening reveals a large signaling network controlling theGolgi apparatus in human cells, " Molecular Systems Biology, vol. 8, article 629, 2012.
76. Y.H.Zhou, L. G. Tang, S.L.Guo et al., "Steroids inthe treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis, " PLoS One, vol. 6, article e8, 2011.
77. H. Suzuki, K. Kiryluk, J. Novak et al., "The pathophysiology of IgA nephropathy, " Journal of the American Society of Nephrology, vol. 22, no. 10, pp. 1795-1803, 2011.